How to tell if Biden drove a hard bargain on drug prices

Taking stock of the drug industry, from the lab to the medicine chest

July 30, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Win McNamee/Getty Images STAT+ | How to tell if Biden drove a hard bargain in Medicare drug price negotiations Drug prices in other countries and the value that treatments deliver for patients are ways to figure out if Medicare drove a hard bargain. By John Wilkerson STAT+ | Older GLP-1 drug may help protect brains of Alzheimer's patients, early study suggests A new study finds that liraglutide slowed shrinkage of the brain in key areas involved with cognitive function, but more research is needed. By Elaine Chen Opinion: How artificial intelligence can bolster Europe's competitive edge in biopharma It's the European Union's time to pave the way for science and AI-based leadership in the biopharmaceutical and health care industries. By Paul Hudson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser